News

Patient dosing and follow-up is underway and the company expects to reveal top-line results later this year. SMT19969 is a novel, oral antibiotic designed to selectively target C.

SL-401 is a targeted therapy directed to the interleukin-3 receptor (IL-3R) present on cancer stem cells (CSCs) and tumor bulk of BPDCN, AML, and other hematologic cancers. It

The facility, dubbed JLABS @ Toronto, is due to open in spring 2016. It will serve as a home for about 50 startups focused on biotechnology and pharmaceuticals,

The update enables the company to use Daklinza in combination with sofosbuvir for 12 weeks in patients without cirrhosis in all 28 Member States of the European Union.

The products include Mucinex DM Regular Strength (guaifenesin 600mg and dextromethorphan 30mg); Mucinex DM Maximum Strength (guaifenesin 1200mg and dextromethorphan 60mg); Mucinex Maximum Strength (guaifenesin 1200mg). Perrigo will

The panel can be analyzed on the full line of nCounter Analysis Systems, including the new nCounter SPRINT™ Profiler, utilizing breakthrough technology, which simultaneously measures both RNA and

Alligent is a leading Medical Affairs agency that develops and delivers strategically-focused, integrated and aligned medical communications solutions to the biopharma industry. The deal was supported by the

The company will undertake the open-label Phase 2 trial in collaboration with MD Anderson Cancer Center in Houston. About 25 patients are expected to be enrolled in the

BL-5010 is a novel product for the non-surgical removal of benign skin lesions. It offers an alternative to painful, invasive and expensive removal treatments including cryotherapy, laser treatment